Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record.

Receptor conversion in distant breast cancer metastases

Open access
Hoefnagel, Laurien DC, van de Vijver, Marc J, van Slooten, Henk-Jan, Wesseling, Pieter, Wesseling, Jelle, Westenend, Pieter J, Bart, Joost, Seldenrijk, Cornelis A, Nagtegaal, Iris D, Oudejans, Joost, van der Valk, Paul, van der Groep, Petra, de Vries, Elisabeth GE, van der Wall, Elsken, van Diest, Paul J · 2010 · Breast Cancer Research

Abstract

Introduction: When breast cancer patients develop distant metastases, the choice of systemic treatment is usually based on tissue characteristics of the primary tumor as determined by immunohistochemistry (IHC) and/or molecular analysis. Several previous studies have shown that the immunophenotype of distant breast cancer metastases may be different from that of the primary tumor (receptor conversion), leading to inappropriate choice of systemic treatment. The studies published so far are however small and/or methodologically suboptimal. Therefore, definite conclusions that may change clinical practice could not yet be drawn. We therefore aimed to study receptor conversion for estrogen receptor alpha (ERα), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in a large group of distant (non-bone) breast cancer metastases by re-staining all primary tumors and metastases with current optimal immunohistochemical and in situ hybridization methods on full sections. Methods: A total of 233 distant breast cancer metastases from different sites (76 skin, 63 liver, 43 lung, 44 brain and 7 gastro-intestinal) were IHC stained for ERα, PR and HER2, and expression was compared to that of the primary tumor. HER2 in situ hybridization (ISH) was done in cases of IHC conversion or when primary tumors or metastases showed an IHC 2+ result. Results: Using a 10% threshold, receptor conversion by IHC for ERα, PR occurred in 10.3%, 30.0% of patients, respectively. In 10.7% of patients, conversion from ER+ or PR+ to ER-/PR- and in 3.4% from ER-/PR- to ER+ or PR+ was found. Using a 1% threshold, ERα and PR conversion rates were 15.1% and 32.6%. In 12.4% of patients conversion from ER+ or PR+ to ER-/PR-, and 8.2% from ER-/PR- to ER+ or PR+ occurred. HER2 conversion occurred in 5.2%. Of the 12 cases that showed HER2 conversion by IHC, 5 showed also conversion by ISH. One further case showed conversion by ISH, but not by IHC. Conversion was mainly from positive in the primary tumor to negative in the metastases for ERα and PR, while HER2 conversion occurred equally both ways. PR conversion occurred significantly more often in liver, brain and gastro-intestinal metastases. Conclusions: Receptor conversion by immunohistochemistry in (non-bone) distant breast cancer metastases does occur, is relatively uncommon for ERα and HER2, and is more frequent for PR, especially in brain, liver and gastro-intestinal metastases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/bcr2645

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 226

Metadata

Authors
Hoefnagel, L. D., van de Vijver, M. J., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., Oudejans, J., van der Valk, P., van der Groep, P., de Vries, E. G., van der Wall, E., & van Diest, P. J.
Venue
Breast Cancer Research
Published
2010-09-23
Volume
12
Issue
5
Pages
R75-R75
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
OpenAlex
W2098479045
Cited by
226
References
0
FWCI
3.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Receptor conversion in distant breast cancer metastases. https://app.cochat.ai/papers/10.1186/bcr2645
The paper
Hoefnagel, L. D., van de Vijver, M. J., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., Oudejans, J., van der Valk, P., van der Groep, P., de Vries, E. G., van der Wall, E., & van Diest, P. J. (2010). Receptor conversion in distant breast cancer metastases. Breast Cancer Research. https://doi.org/10.1186/bcr2645

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.